このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Antiplatelet Therapy Continuation in Spine Surgery - Its Effect on Postoperative Morbidity and Mortality

2009年10月30日 更新者:Tel-Aviv Sourasky Medical Center

Impact of Continued Use of Clopidogrel and / or Aspirin on Outcomes in Patients Undergoing Lumbar Spine Surgery. A Prospective Observational Study

The objective of this study is to evaluate the safety of antiplatelet (APA)therapy continuation in patients undergoing lumbar spine surgery (laminectomy, discectomy and foraminotomy), and to gather evidence-based data regarding postoperative outcomes potentially related to APA management.

調査の概要

状態

わからない

条件

詳細な説明

BACKGROUND Antiplatelet agents (APAs) are widely prescribed for coronary stenting, primary and secondary prevention of cerebrovascular and coronary artery disease. Dual antiplatelet therapy (aspirin/plavix) has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Maintaining antiplatelet therapy until the end of the indicated period is crucial for the success of coronary stents. Premature discontinuation of antiplatelet therapy markedly increases the risk of stent thrombosis, a catastrophic event that frequently leads to myocardial infarction (MI), with a death rate of 20-40%. Aspirin is commonly prescribed for lifetime in patients at increased atherothrombotic risk, whereas Plavix is regarded as mandatory until the coronary stents are fully endothelialized, which takes 4-6 weeks for bare metal stents and up to 1 yr for drug-eluting stents. And yet, within the first year after stenting, approximately 5% of patients who have undergone percutaneous coronary interventions (PCIs) will require noncardiac surgery, thus raising dilemmas of APA management: stopping APA treatment before operation to avoid bleeding while risking postoperative stent thrombosis versus maintaining APA therapy perioperatively thus risking extensive blood loss but limiting the risks of postoperative ischemic events.

Current recommendations are that aspirin should not be discontinued pre-operatively, with the exception of brain surgery and certain urological operations in which bleeding may be difficult to control and is therefore life threatening.

The continued use of plavix during the perioperative period significantly increases intraoperative blood loss, re-operations for the control of hemorrhage and transfusions, but does not affect morbidity, mortality, or surgical outcomes.

Most guidelines recommend to postpone invasive procedures until the end of the indication for plavix. Only vital or emergency surgery should be performed on full antiplatelet therapy, with the exception of procedures in which even a small hemorrhage may have disastrous consequences (e.g. intracranial surgery, spinal surgery in the medullary canal, surgery of the posterior chamber of the eye), or procedures involving massive bleeding.

Evidence-based data are needed to guide management of patients in whom early antiplatelet withdrawal is being considered (e.g. those who require non-cardiac surgery). Several studies have been conducted in orthopedic and cardiac surgery, however, to the best of our knowledge, not in spine surgery. This type of surgery might often be semi-urgent and postponing surgery for long time may be problematic.

This prospective, observational study is designed to evaluate the safety of APA therapy continuation in patients admitted for lumbar spine surgery.

METHODS

Study design The study will be conducted as an observational one. An informed consent will be obtained from all patients matching the above criteria. Diuretics and oral hypoglycemics will be discontinued the day prior to surgery, as dictated by the routines in our patients. Antiplatelet therapy will be continued as commonly practiced in these procedures. Any deviation from this protocol will be documented. Throughout the postoperative period study patients will be observed for any bleeding- or thrombosis-related events, and relevant perioperative data will documented (see "patient monitoring & assessment").

Peri-operative management Anesthetic and surgical management, including management of surgical hemorrhage or any other hemodynamic event will adhere to standard practice. Postoperatively, study patients will be transferred to the post-anesthesia care unit and later to the neurosurgery department, unless otherwise indicated. In the postoperative period, departmental routines will guide blood product transfusions, pain management, fluid regimens and medications administered.

Patient monitoring & assessment

Patients will be allocated into 4 groups:

  1. Patients not at risk of coronary and/or cerebrovascular disease, and not taking APAs.
  2. Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
  3. High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
  4. Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.

For each consented patient included in the study we will record demographics and medical history ; chronic medications ; detailed cardiovascular history ; neurological examination ; APA-related data: type and dose of APA taken; indication ; Intra-operative data ; and perioperative complications.

Outcome measures

  1. Primary outcomes: hemorrhagic, thrombotic, and neurological complications Include any complication, morbidity or death potentially caused by continuation (e.g., direct or indirect hemorrhage; hemorrhagic CVA) or withdrawal of APA therapy (e.g., MI; PE; ischemic CVA; DVT; etc.), occurring until discharge, or within 30 postoperative days. Neurological complications may be related to surgery; bleeding; thrombosis; other, and will be classified accordingly.
  2. Secondary outcomes Include: re-intubations; transfer to ICU; length of stay (LOS); re-admissions within 7 / 30 days; major morbidity or death 30 and 60 days postoperatively.

Study size The study is expected to last 2 years, and to include approximately 200 patients.

REFERENCES

  1. Anderson, J.L., et al., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol, 2007. 50(7): p. e1-e157.
  2. Fox, K.A., et al., Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation, 2004. 110(10): p. 1202-8.
  3. Hirsch, A.T., et al., ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation, 2006. 113(11): p. e463-654.
  4. Keller, T.T., A. Squizzato, and S. Middeldorp, Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev, 2007(3): p. CD005158.
  5. Smith, S.C., Jr., et al., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 2006. 113(19): p. 2363-72.
  6. Weitz, J.I., J. Hirsh, and M.M. Samama, New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133(6 Suppl): p. 234S-256S.
  7. Grines, C.L., et al., Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 2007. 115(6): p. 813-8.
  8. Iakovou, I., et al., Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005. 293(17): p. 2126-30.
  9. Patrono, C., et al., Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133(6 Suppl): p. 199S-233S.
  10. Pfisterer, M., et al., Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol, 2006. 48(12): p. 2584-91.
  11. Ong, A.T., et al., Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 2005. 45(12): p. 2088-92.
  12. Schouten, O., J.J. Bax, and D. Poldermans, Management of patients with cardiac stents undergoing noncardiac surgery. Curr Opin Anaesthesiol, 2007. 20(3): p. 274-8.
  13. Laffey, J.G., J.F. Boylan, and D.C. Cheng, The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology, 2002. 97(1): p. 215-52.
  14. Priebe, H.J., Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth, 2004. 93(1): p. 9-20.
  15. Ho, P.M., et al., Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA, 2008. 299(5): p. 532-9.
  16. Ferrari, E., et al., Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol, 2005. 45(3): p. 456-9.
  17. Sharma, A.K., et al., Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv, 2004. 63(2): p. 141-5.
  18. Chassot, P.G., A. Delabays, and D.R. Spahn, Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth, 2007. 99(3): p. 316-28.
  19. Chu, M.W., et al., Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg, 2004. 78(5): p. 1536-41.
  20. Douketis, J.D., et al., The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133(6 Suppl): p. 299S-339S.

研究の種類

観察的

入学 (予想される)

200

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Tel Aviv、イスラエル、64239
        • Tel Aviv Sourasky Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~90年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Patients admitted for lumbar laminectomy, discectomy or foraminotomy.

説明

Inclusion Criteria:

  • Aged > 18 years old,
  • Undergoing elective or urgent spinal surgery,
  • Included are procedures aimed to decompress the spinal canal in the lumbar region due to a degenerative disease, i.e., laminectomy, discectomy and foraminotomies.

Exclusion Criteria:

  • Patients with an infectious disease, tumor resection, trauma cases, or
  • Patients requiring lumbar fixation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Low-risk patients, not on APAs
Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
High-risk patients, not on APAs
Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
APA for primary prevention
High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
APA for secondary prevention
Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Postoperative hemorrhagic, thrombotic, and neurological complications
時間枠:60 days
60 days

二次結果の測定

結果測定
時間枠
滞在日数
時間枠:30日
30日

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Idit Matot, MD、Tel-Aviv Sourasky Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2010年1月1日

一次修了 (予想される)

2012年1月1日

研究の完了 (予想される)

2012年2月1日

試験登録日

最初に提出

2009年10月30日

QC基準を満たした最初の提出物

2009年10月30日

最初の投稿 (見積もり)

2009年11月1日

学習記録の更新

投稿された最後の更新 (見積もり)

2009年11月1日

QC基準を満たした最後の更新が送信されました

2009年10月30日

最終確認日

2009年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • TASMC-09-IM-0540-CTIL

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。